Ranbaxy Laboratories CEO Malvinder Singh said that due to an import ban by the US authorities, his firm may shift some generic drug production from India to the US.

"We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets," said Mr Singh, at a media reception held by Japanese drugmaker Daiichi Sankyo.

Dada aka the Cricket legend Sourav Ganguly is all set to receive a one-kilogram gold bat at a Cricket Association of Bengal (CAB) felicitation programme on Sunday. The cost of the bat is expected to be around Rs 25 lakh. The gold bat has Ganguly's cricketing records embossed on it.

Speaking on this, Jagmohan Dalmiya, CAB President said, “It will be a totally cricket-centric function. So, there will be no cultural programmes.”

A15 minutes film which will portray Ganguly's life from a child till his retirement as a cricketer would also be shown in the programme.

Now the public will get to watch the serial kisser Emraan Hashmi in a "different" role in his forth coming film "Raaz - The Mystery Continues" (RTMC), in which he plays the role of a brooding painter. So finally Emraan is set to spook the audiences with something else other than his trademark multitude of kisses!

Thanks to continued buying across board, the benchmark indices Sensex and Nifty have gained significant ground in the positive terrain and look strong on course to close the week on a bright note today (Friday, January 16).

Oil & gas and power stocks were in limelight while realty stocks traded weak.

Secondline stocks traded on a flat note with positive bias. BSE Midcap gained 0.45%, while Smallcap index fell 0.06%.

The latest report of UNICEF paints a grim picture on the part of Uttar Pradesh. The report, considered as a wake-up call for the people of UP, highlights the alarming figures on maternal and neonatal mortality in the state.

Country’s largest pharmaceutical company, Ranbaxy Laboratories Limited, announced that it has acquired manufacturing facilities that have the approval from the U.S. Food and Drug Administration (FDA).

Speaking on this, Malvinder Singh, CEO Ranbaxy Laboratories said, “We will transfer (production of) some products from India to America. Also, we are looking at making some acquisitions of manufacturing assets.”

He added that apart from US, his company is also keeping its options open to buy FDA-approved facilities from other countries.